vs
ABEONA THERAPEUTICS INC.（ABEO）与阿斯利康（AZN）财务数据对比。点击上方公司名可切换其他公司
Abeona Therapeutics是一家临床阶段生物制药公司，专注于研发针对致命罕见遗传病的创新基因与细胞疗法，其管线覆盖多种未被满足的临床需求，主要为北美、欧洲地区缺乏有效治疗方案的患者群体服务。
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
ABEO vs AZN — 直观对比
营收规模更大
AZN
是对方的Infinity倍
$0
损益表 — Q3 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $14.5B |
| 净利润 | $-5.2M | $2.4B |
| 毛利率 | — | 82.9% |
| 营业利润率 | — | 24.3% |
| 净利率 | — | 16.9% |
| 营收同比 | — | 11.7% |
| 净利润同比 | 82.9% | 27.0% |
| 每股收益（稀释后） | $-0.10 | $1.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABEOAZN
| Q3 25 | $0 | — | ||
| Q2 25 | $400.0K | $14.5B | ||
| Q2 24 | — | $12.9B | ||
| Q2 23 | — | $11.4B | ||
| Q2 22 | — | $10.8B |
净利润ABEOAZN
| Q3 25 | $-5.2M | — | ||
| Q2 25 | $108.8M | $2.4B | ||
| Q2 24 | — | $1.9B | ||
| Q2 23 | — | $1.8B | ||
| Q2 22 | — | $360.0M |
毛利率ABEOAZN
| Q3 25 | — | — | ||
| Q2 25 | — | 82.9% | ||
| Q2 24 | — | 83.1% | ||
| Q2 23 | — | 82.8% | ||
| Q2 22 | — | 72.2% |
营业利润率ABEOAZN
| Q3 25 | — | — | ||
| Q2 25 | -5698.0% | 24.3% | ||
| Q2 24 | — | 21.2% | ||
| Q2 23 | — | 21.5% | ||
| Q2 22 | — | 5.0% |
净利率ABEOAZN
| Q3 25 | — | — | ||
| Q2 25 | 27208.3% | 16.9% | ||
| Q2 24 | — | 14.9% | ||
| Q2 23 | — | 15.9% | ||
| Q2 22 | — | 3.3% |
每股收益（稀释后）ABEOAZN
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.71 | $1.57 | ||
| Q2 24 | — | $1.24 | ||
| Q2 23 | — | $1.17 | ||
| Q2 22 | — | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $207.1M | $7.1B |
| 总债务越低越好 | $19.8M | — |
| 股东权益账面价值 | $171.2M | $44.8B |
| 总资产 | $231.1M | $112.4B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资ABEOAZN
| Q3 25 | $207.1M | — | ||
| Q2 25 | $225.5M | $7.1B | ||
| Q2 24 | — | $6.9B | ||
| Q2 23 | — | $5.7B | ||
| Q2 22 | — | $4.8B |
总债务ABEOAZN
| Q3 25 | $19.8M | — | ||
| Q2 25 | $19.6M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
股东权益ABEOAZN
| Q3 25 | $171.2M | — | ||
| Q2 25 | $163.6M | $44.8B | ||
| Q2 24 | — | $39.6B | ||
| Q2 23 | — | $37.4B | ||
| Q2 22 | — | $36.0B |
总资产ABEOAZN
| Q3 25 | $231.1M | — | ||
| Q2 25 | $246.2M | $112.4B | ||
| Q2 24 | — | $104.3B | ||
| Q2 23 | — | $96.5B | ||
| Q2 22 | — | $96.6B |
负债/权益比ABEOAZN
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-23.7M | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABEOAZN
| Q3 25 | $-21.2M | — | ||
| Q2 25 | $-18.8M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流ABEOAZN
| Q3 25 | $-23.7M | — | ||
| Q2 25 | $-21.7M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流率ABEOAZN
| Q3 25 | — | — | ||
| Q2 25 | -5421.3% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
资本支出强度ABEOAZN
| Q3 25 | — | — | ||
| Q2 25 | 725.3% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金转化率ABEOAZN
| Q3 25 | — | — | ||
| Q2 25 | -0.17× | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
